Poly Medicure Ltd

Poly Medicure Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Poly Medicure Ltd

₹ 2,841 -2.24%
13 Dec - close price
polymedicure.com BSE: 531768 NSE: POLYMED
About

Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]

Key Points

Product Portfolio
It is a medical devices company with product portfolio comprises of more than 130 SKUs of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. [1]

Website BSE NSE
  • Market Cap ₹ 28,788 Cr.
  • Current Price ₹ 2,841
  • High / Low ₹ 3,358 / 1,361
  • Stock P/E 97.6
  • Book Value ₹ 256
  • Dividend Yield 0.11 %
  • ROCE 23.6 %
  • ROE 19.1 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 31.9% CAGR over last 5 years

Cons

  • Stock is trading at 11.1 times its book value
  • Promoter holding has decreased over last quarter: -3.47%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Part of BSE 250 SmallCap Index Nifty Smallcap 250 BSE 500 Nifty 500 Multicap 50:25:25 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
223 230 258 249 275 285 307 321 337 340 378 385 420
172 179 202 202 210 214 224 234 253 249 281 281 305
Operating Profit 51 51 56 46 65 71 83 87 84 90 97 104 115
OPM % 23% 22% 22% 19% 24% 25% 27% 27% 25% 27% 26% 27% 27%
13 8 8 5 9 15 9 14 15 17 15 17 27
Interest 0 -1 1 1 0 5 2 2 2 3 3 3 3
Depreciation 14 14 14 14 14 14 15 16 16 16 16 20 21
Profit before tax 50 46 49 36 59 67 75 83 81 88 92 98 118
Tax % 24% 25% 26% 26% 27% 25% 22% 24% 23% 26% 26% 25% 26%
38 35 36 27 44 50 59 63 62 65 68 74 87
EPS in Rs 3.99 3.60 3.77 2.81 4.54 5.21 6.13 6.54 6.48 6.78 7.12 7.71 8.63
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
259 322 390 411 454 519 610 687 785 922 1,115 1,375 1,522
206 246 304 323 361 397 479 520 569 707 847 1,013 1,116
Operating Profit 53 76 86 88 93 122 131 166 216 215 267 362 406
OPM % 20% 24% 22% 21% 21% 23% 22% 24% 28% 23% 24% 26% 27%
0 11 28 8 14 16 20 21 22 40 38 60 77
Interest 7 9 10 10 8 12 14 20 11 6 11 14 13
Depreciation 13 14 19 21 24 29 37 41 48 54 57 64 73
Profit before tax 33 63 85 65 75 97 100 126 180 195 237 344 397
Tax % 30% 30% 27% 27% 27% 27% 35% 24% 25% 25% 25% 25%
24 45 62 48 55 71 65 96 136 147 179 258 295
EPS in Rs 2.75 5.11 7.07 5.47 6.25 8.00 7.41 10.86 14.17 15.28 18.69 26.91 30.24
Dividend Payout % 9% 20% 18% 27% 40% 25% 27% 18% 18% 16% 16% 11%
Compounded Sales Growth
10 Years: 16%
5 Years: 18%
3 Years: 21%
TTM: 22%
Compounded Profit Growth
10 Years: 21%
5 Years: 32%
3 Years: 24%
TTM: 26%
Stock Price CAGR
10 Years: 30%
5 Years: 69%
3 Years: 44%
1 Year: 82%
Return on Equity
10 Years: 18%
5 Years: 17%
3 Years: 16%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 11 22 22 22 44 44 44 44 48 48 48 48 51
Reserves 101 124 174 207 227 294 337 391 918 1,040 1,194 1,422 2,541
49 67 79 82 101 133 161 207 137 127 149 174 161
53 73 89 76 85 94 112 126 121 163 187 214 300
Total Liabilities 214 286 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,052
92 123 165 182 207 265 306 363 426 488 635 867 972
CWIP 8 20 10 14 20 18 19 25 21 43 78 76 62
Investments 4 3 4 4 3 17 8 25 354 346 132 167 1,090
110 140 185 187 227 264 321 354 422 499 732 748 928
Total Assets 214 286 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,052

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
39 66 63 63 56 75 106 128 119 123 191 266
-31 -58 -59 -31 -56 -88 -101 -107 -436 -85 -179 -241
-8 5 -6 -31 -0 16 -5 -21 317 -35 -13 -20
Net Cash Flow 0 13 -2 1 0 3 1 1 0 3 -1 5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 61 52 59 74 77 79 77 68 72 82 77 72
Inventory Days 149 142 148 114 194 161 186 241 217 218 237 205
Days Payable 99 101 101 76 131 96 123 142 111 115 105 89
Cash Conversion Cycle 111 94 106 111 140 144 139 166 179 185 209 188
Working Capital Days 56 31 45 65 81 94 83 73 107 116 112 100
ROCE % 27% 33% 30% 26% 24% 26% 22% 25% 22% 17% 18% 24%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
44.76% 44.66% 53.34% 53.33% 53.33% 53.32% 53.32% 53.17% 53.17% 53.14% 66.02% 62.56%
14.13% 15.07% 15.59% 16.27% 16.33% 16.21% 15.61% 14.49% 14.10% 12.37% 9.91% 11.88%
2.99% 3.33% 3.25% 3.39% 3.38% 3.67% 4.25% 5.15% 5.46% 7.21% 9.34% 12.33%
38.11% 36.94% 27.82% 27.02% 26.97% 26.79% 26.82% 27.20% 27.28% 27.25% 14.72% 13.23%
No. of Shareholders 35,16633,83133,29634,23932,01535,39336,14134,64936,05336,71236,85238,352

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls